215 related articles for article (PubMed ID: 28705090)
1. The safety of available treatments options for neuroendocrine tumors.
Faggiano A; Lo Calzo F; Pizza G; Modica R; Colao A
Expert Opin Drug Saf; 2017 Oct; 16(10):1149-1161. PubMed ID: 28705090
[TBL] [Abstract][Full Text] [Related]
2. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
[TBL] [Abstract][Full Text] [Related]
3. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
Cloyd JM; Konda B; Shah MH; Pawlik TM
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
[TBL] [Abstract][Full Text] [Related]
5. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities.
Shaheen S; Moradi F; Gamino G; Kunz PL
Curr Treat Options Oncol; 2020 Mar; 21(4):25. PubMed ID: 32172368
[TBL] [Abstract][Full Text] [Related]
6. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
Bodei L; Pepe G; Paganelli G
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
[TBL] [Abstract][Full Text] [Related]
7. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors.
Koffas A; Toumpanakis C
Expert Opin Drug Saf; 2021 Mar; 20(3):321-334. PubMed ID: 33338383
[No Abstract] [Full Text] [Related]
8. [Treatment of neuroendocrine tumors with radio-labeled somatostatin analogues].
Bober B; Zaleska M; Kołodziej M; Kowalski Ł; Saracyn M
Wiad Lek; 2018; 71(9):1770-1773. PubMed ID: 30737938
[TBL] [Abstract][Full Text] [Related]
9. Update on medical treatment of small intestinal neuroendocrine tumors.
Pusceddu S; Femia D; Lo Russo G; Ortolani S; Milione M; Maccauro M; Vernieri C; Prinzi N; Concas L; Leuzzi L; De Braud F; Buzzoni R
Expert Rev Anticancer Ther; 2016 Sep; 16(9):969-76. PubMed ID: 27353232
[TBL] [Abstract][Full Text] [Related]
10. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
[TBL] [Abstract][Full Text] [Related]
11. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
12. Peptide Receptor Radiotherapy: Current Approaches and Future Directions.
Kong G; Hicks RJ
Curr Treat Options Oncol; 2019 Aug; 20(10):77. PubMed ID: 31468210
[TBL] [Abstract][Full Text] [Related]
13. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
de Visser M; Verwijnen SM; de Jong M
Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
15. [Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)].
Papamichail DG; Exadaktylou PE; Chatzipavlidou VD
Hell J Nucl Med; 2016; 19(1):75-82. PubMed ID: 27035909
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.
Bodei L; Kwekkeboom DJ; Kidd M; Modlin IM; Krenning EP
Semin Nucl Med; 2016 May; 46(3):225-38. PubMed ID: 27067503
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours.
Khan MS; Caplin ME
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S53-74. PubMed ID: 22005115
[TBL] [Abstract][Full Text] [Related]
18. Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms.
Tsoli M; Alexandraki K; Xanthopoulos C; Kassi E; Kaltsas G
Horm Metab Res; 2020 Aug; 52(8):614-620. PubMed ID: 32108932
[TBL] [Abstract][Full Text] [Related]
19. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
20. Case report of a patient with initially inoperable well-differentiated midgut neuroendocrine tumor (WDNT)--PRRT and long-acting somatostatin analogs as the neoadjuvant therapy.
Sowa-Staszczak A; Pach D; Stefańska A; Szybiński P; Kulig J; Tomaszewska R; Chrzan R; Hubalewska-Dydejczyk A
Nucl Med Rev Cent East Eur; 2012 Aug; 15(2):137-9. PubMed ID: 22936508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
